Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of Sanqi Granules for primary chronic glomerulonephritis with qi deficiency and blood stasis syndrome
CTR20263689Phase 2Active
- Sponsor
- Guangxi Zhongheng Innovation Pharmaceutical Research
- Start
- Oct 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic primary glomerulonephritis (CPGN), IgA nephropathy (IgAN) and idiopathic membranous glomerulonephritis (IMG) comparing Sanqi Granules with Placebo comparator (2 arms). Started Oct 2026; status: active.
02
Drugs
Sanqi Granules
03
Conditions
chronic primary glomerulonephritis (CPGN)IgA nephropathy (IgAN)idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20263689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263689.